#JustIn: First International Consensus on Fibromuscular Dysp
The “First international consensus on the diagnosis and management of fibromuscular dysplasia” (FMD) has been published in the journal Vascular Medicine and the Journal of Hypertension. The consensus document was written by a committee of international experts in the field commissioned by the Society for Vascular Medicine (SVM) and the Working Group “Hypertension and the Kidney” of the European Society of Hypertension (ESH).

This comprehensive review of FMD provides a harmonization and update to two prior European and US scientific statements and covers pathophysiology, nomenclature, differential diagnosis, diagnostic evaluation, management, and longitudinal follow-up as well as the current status of FMD registries and FMD patient advocacy organizations around the world.

Some highlights of the consensus points include:

- At least one focal or multifocal arterial lesion on imaging is required to establish the diagnosis of FMD. The presence of aneurysm, dissection, or tortuosity alone is inadequate to establish the diagnosis.

- Regardless of initial site of vascular bed involvement, patients with FMD should undergo brain to pelvis imaging, at least once and usually with CTA or contrast-enhanced MRA, to identify other areas of FMD, as well as to screen for occult aneurysms and dissections.

- Treatment with antiplatelet therapy (aspirin 75–100 mg/day) is reasonable to prevent thrombotic and thromboembolic complications, in the absence of contraindication.

- A standardized consensus-based protocol for renal angiography and angioplasty is proposed, which includes hemodynamic assessment of FMD lesions using translesional pressure gradient measurements.

Note: This list is a brief compilation of some of the key points included in the document and is not exhaustive and does not constitute medical advice. Kindly refer to the original publication here: https://pxmd.co/SG4sS, https://pxmd.co/ot2Zz
1 share